Company ProfilePremium

Total Brain Limited

Company Profile Analysis

Ticker: BRC.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Total Brain Limited - Company showcase

Year Founded & Workforce

2000

Total Brain Limited logo

Total Brain Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Total Brain Limited Overview

For over two decades, Total Brain Limited, previously Brain Resource, sat at the meeting point of academic neuroscience and commercial digital health. It built what it called the world's largest standardized brain database. That database came from the Brain Resource International Database and the landmark iSPOT-Depression and iSPOT-ADHD treatment-prediction studies. Between 2018 and 2022, the company repackaged this scientific asset into "Total Brain". This was a SaaS mental-health monitoring and self-care platform sold to US employers, affinity groups, insurers, clinical providers and government programs, including an IBM-led deployment for the US Department of Veterans Affairs. The science was credible and the partners were blue-chip. Even so, revenue stayed small: roughly A$2.6m in FY2019 and A$8.4m in FY2022, the latter flattered by one-off data licences. Cash burn was persistent, and in August 2022 the board agreed to sell the business to SonderMind for US$10m. Total Brain is best understood today as a completed exit and a case study in sub-scale digital-health commercialization. It is no longer an investable listed entity.


Company's own description (FY2019–FY2022 filings and releases). Total Brain described itself as an applied, integrative neuroscience company. It said it had built a mental health monitoring and support platform powered by the world's largest standardized brain database. The platform was meant to let individuals scientifically measure and optimize their brain capacities while managing the risk of common mental conditions (FY2019 Annual Report; ASX quarterly 4C releases 2019–2021). It claimed to measure 12 brain capacities that define mental health and to screen for the risk of 7 common mental health conditions (company investor update, early 2021, as reported by Stockhead).

Business model. Total Brain operated a business-to-business-to-consumer (B2B2C) SaaS model. Paying customers were organizations, not individuals:

Revenue mix characterization. Revenue was mostly subscription SaaS, with occasional large licensing items. In FY2022 (A$8.42m reported revenue, per MarketScreener aggregation of the FY2022 annual report), a material but not separately verified share came from the one-off Janssen and Alto data licences. That means FY2022 headline revenue overstates the recurring run-rate. ARR, the better recurring measure, was about A$4.0m at December 2020 (+46% YoY) (company update, Jan 2021, reported by Stockhead).

Value chain position. Total Brain was an upstream "measurement and insight" layer. It assessed, screened and tracked brain-health capacities and delivered self-care exercises, but it did not provide therapy or clinical treatment. That gap is exactly why SonderMind acquired it: SonderMind delivers therapy and wanted measurement-based-care tooling upstream and downstream of the therapy session.

End-markets served. Employer mental-health benefits (corporate wellness and EAP adjacency), consumer brain fitness, behavioral-health measurement-based care, veteran and government transition programs, and pharmaceutical precision-psychiatry R&D.

Independent characterization. Total Brain's lasting asset was its scientific data (iSPOT-D, iSPOT-ADHD, the standardized brain database of more than one million users), not its software. Within one year it monetized that data twice through one-off licences (Janssen, Alto). In the same period, the employer SaaS business competed against far better-funded US venture-backed platforms (Lyra, Spring Health, Modern Health, Headspace/Ginger). The business therefore depended on financing: the board repeatedly raised equity (A$10m in FY2018, A$14m in November 2019) and convertible debt (A$1.28m, April 2022) to fund operating outflows of about A$2.9m per quarter by late 2021.

Strategy

Stated strategy themes (FY2019–FY2021 annual reports and quarterlies), paraphrased:

  1. Science as the moat. Use the standardized brain database and about two decades of validated neuroscience to separate Total Brain from consumer brain-training and meditation apps.

  2. B2B2C distribution. Grow Corporate ARR by penetrating existing channel partners and running account-based marketing aimed at the largest US enterprises. FY2019 produced more than 160 new marketing leads (Kalkine, Sept 2019).

  3. Three-channel growth engine: Corporate, Affinity and Clinical, with an ARR pipeline of A$8.9m flagged in January 2021.

  4. Government scale via IBM. Use IBM's Mental Fitness 360 to reach populations in transition, starting with US veterans (18m potential population cited).

  5. Operating leverage. Hold the cost base roughly flat while growing revenue. Management said in January 2021 that 2020 investments had positioned the company for this.

  6. Product extension. Biometrics (HRV wearables), genetics and clinical measurement-based care.

  7. Data monetization. Non-exclusive licensing of iSPOT-D and other research data to pharma and precision-psychiatry developers (2021–2022).

Medium-term targets. In CY2019, management set an objective of 100% revenue growth to US$3.2m and 100% growth in user registrations and Brain Profiles (Dec 2018 quarterly). This was not met: FY2020 revenue was about A$3.9m, roughly US$2.6m. There was no guidance after the sale. ESG commitments and cost-program targets were not publicly disclosed.

Product Portfolio

Product / assetDescriptionKey capabilitiesTarget customerLaunch / latestPricing model

Total Brain platform (core)

Neuroscience-based mental health and brain-performance monitoring and self-care SaaS app (web, iOS, Android)

Assesses 12 brain capacities across core domains (emotion, feeling, cognition, self-control); screens risk for 7 common conditions; personalized brain and mind/body training; longitudinal tracking

Employees of corporate clients; affinity-group members; clinical patients

Launched Q3 CY2018 after 9 months of development; iterated through 2022

Per-member annual SaaS subscription (ARR)

—

Aggregated, de-identified population dashboards for employers

Team-level brain-health and risk analytics; ROI reporting

HR / benefits leaders

2018 onward

Bundled in corporate SaaS

Clinical Insights / provider monitoring

Monitoring module for measurement-based care

Ongoing symptom and capacity tracking between visits

Providers, payers, insurers

2019–2022

SaaS licence; reimbursement-code strategy flagged (Mar 2020)

HRV wearable functionality (Discrete and Continuous HRV)

Heart-rate-variability stress measurement using wrist wearables

Company said Discrete HRV was about 90% accurate versus chest-strap gold standard, and Continuous HRV about 4x more accurate than the next-best alternative with 30x signal resolution. Pilot: 6.4 engagements per day and a 25% stress reduction over 3 months

All channels

Launched March 2021 quarter

Upsell feature (pricing not disclosed)

Mental Fitness 360 / GRIT integration (with IBM)

Total Brain embedded as core functionality in IBM's Thrive360 / Mental Fitness 360 platform and the GRIT app for transitioning veterans

Mental fitness, social connection and wellbeing tools for populations in transition

US Dept of Veterans Affairs; large government populations

Partnership Aug 2019; VA deployment 2021 (25,000 users; scalable to about 200,000)

Sub-licence through IBM; about A$570–590k ARR initial, up to about A$3.5m ARR at scale (company estimates)

Everyday Health integration

Mental-health and fitness content embedded in Everyday Health web portal

Content delivery to 44m monthly unique users

Consumers via affinity partner

Signed Sept 2019 quarter

Licence/content fee

D2C licence (Hamptons Life)

Exclusive perpetual global licence to build a consumer version

Separate D2C product

Consumers

—

A$6m upfront (recognized over 3 years), A$0.35m p.a. maintenance; TTB option on 50% equity

focus@will B2C distribution

Revenue-share distribution through focus@will music-for-focus app

Monthly fee; revenue share

Consumers

Sept 2018 quarter

Subscription revenue share

iSPOT-D research dataset

International Study to Predict Optimized Treatment for Depression; standardized biomarker and clinical data

Treatment-response prediction research

Pharma / biotech (Janssen R&D; Alto Neuroscience)

Study 2000s–2010s; licences late 2021 and Jan 2022

One-off non-exclusive licence (Janssen US$2.2m)

iSPOT-ADHD dataset

ADHD treatment-prediction study data

Precision psychiatry

Research, pharma

2010s

—

Brain Resource International Database (BRID)

Standardized brain database (EEG, cognition, emotion, genetics) built over about two decades; about A$50m cumulative R&D (RaaS)

Normative comparisons; underpins all products

Internal / licensing

2000s onward

Not separately monetized except via licences

WebNeuro (legacy)

Web-based neurocognitive and emotional assessment for clinicians

Depression evaluation; FDA clearance sought in 2012

Clinicians

~2009; superseded

Per-assessment (historical)

MyBrainSolutions (legacy)

Brain-training and self-help platform; carried AARP users

Brain training; employer programs

Consumers; employers

~2010; migrated to Total Brain 2018–19 (more than 600,000 users, 23 corporate clients and 5 channel partners transferred)

Subscription

Brain Training Platform and Clinical Decision Support (legacy web products)

Earlier products built on iSPOT data

Training; clinician decision support

Consumers; clinicians

Pre-2018

—

“—” = not publicly disclosed.

Financial Narrative

Income statement

Notes and sources:

  • FY2018 revenue is derived as A$2,602,137 ÷ 0.995. The FY2018 loss is A$23,101,340 per the FY2019 Appendix 4E. Kalkine (Sept 2019) cited A$23,947,680. The discrepancy may reflect total versus attributable loss, and the 4E figure is preferred.

  • FY2019 revenue was A$2,602,137 and the loss A$8,570,754 (FY2019 Appendix 4E). No dividends were paid, recommended or declared in FY2019 (same source).

  • FY2020 revenue is derived from the +48.4% growth reported in the FY2020 Annual Report (cited by Motley Fool, Oct 2020). Expenses grew about 3% in FY2020 (same source).

  • FY2021 revenue of 3.694 comes from Preqin, currency unconfirmed. FY2021 growth is derived and should be treated as indicative only.

  • FY2022 revenue of A$8.42m and net loss of A$14.5m come from MarketScreener's aggregation of FY2022 results (released 30 Aug 2022). Eulerpool independently computes a -172.3% net margin for the latest year and -883.1% "a few years ago", which matches FY2022 and FY2018 above.

  • EBITDA forecasts by RaaS (July 2020) were not actuals and are excluded.

Revenue CAGR FY2018–FY2022: about 33.9% per year (A$2.62m to A$8.42m). This is flattered by FY2022 one-off data-licence income (Janssen US$2.2m, about A$3m at the time, plus Alto Neuroscience). On an ARR basis, the recurring business grew roughly 46% in CY2020 and then stalled through COVID-delayed sales cycles in 2021.

Trailing twelve months to 31 December 2022 (final reporting period)

Source: Simply Wall St (TTM based on H1 FY2023 report, released 28 Feb 2023). The negative gross profit probably reflects how staff and delivery costs were classified and transaction-related items in the period of the sale. It is not evidence of negative unit economics on its own.

Balance sheet and liquidity: notes and sources

Sources: RaaS Update (30 Jul 2020), net cash A$11.1m at 30 June 2020. Simply Wall St (Yahoo, 2019) noted no debt on the balance sheet. FY2018 debt of zero follows the A$14m debt-to-equity conversion during FY2018 (FY2018 Annual Report). FY2019 Appendix 4E gives NTA. MarketScreener gives FY2022 net debt of A$0.50m, consistent with the April 2022 A$1.28m convertible note from Zoltan Varga less remaining cash. A legacy aggregator (Eulerpool) shows "current assets" of A$14.69m and A$6.75m for unlabelled recent years; these could not be reconciled with filings and are excluded.

Cash flow

Sources: RaaS (30 Jul 2020): FY20 cash receipts A$4.997m, +81.5%; FY19 receipts derived as A$4.997m ÷ 1.815. Net outflows of A$6.647m (FY20) and A$7.021m (FY19) are from the RaaS cash table. The June 2020 quarter showed a net operating inflow of A$0.31m, helped by a A$1.0m upfront payment on a 3-year contract.

Quarterly cash indicator, September 2021 quarter: receipts A$0.554m; net operating outflow A$2.865m; staff costs about A$2.4m (Appendix 4C, via Stockhead). The annualized burn of about A$11.5m against roughly A$2m of quarterly receipts at best was the immediate cause of the strategic review.

Capex, free cash flow, dividends paid and buybacks: the company paid no dividends and conducted no buybacks while listed. The post-sale return of capital (A$0.0475 per share, 14 Feb 2023) was a liquidation-style distribution, not a buyback, even though the August 2022 plan contemplated a buy-back facility (RaaS, 8 Aug 2022).

Commentary on trends and inflections

Three phases stand out:

  1. FY2017–FY2018 restructuring. Revenue fell 17% in FY2017. Under new CEO Louis Gagnon, FY2018 brought heavy losses (A$23.1m, inflated by restructuring and non-cash items around the A$14m debt conversion), a recapitalization, and the relaunch of the product as Total Brain.

  2. FY2019–FY2020 rebuild. Revenue was flat at A$2.6m in FY2019 because growth in the corporate channel (+33%) was offset by the deliberate run-off of legacy lines (-36%). FY2020 delivered +48.4% revenue growth with costs up only about 3%, receipts up 81.5%, a strong balance sheet after the A$14m November 2019 placement, and A$11.1m of net cash.

  3. FY2021–FY2022 stall and exit. COVID-19 caused delays of up to nine months in enterprise and government pipelines, and the IBM/VA contract slipped repeatedly through early 2021. ARR growth did not convert into revenue (FY2021 roughly flat). FY2022 revenue more than doubled only because of non-recurring data licences, while the loss widened to A$14.5m and the auditor flagged going-concern uncertainty. The company then sold itself.

The persistent gap between broker forecasts and actual results is striking. RaaS (July 2020) forecast A$5.4m revenue for FY2020, A$12.6m for FY2021 and A$21.5m for FY2022, with EBITDA reaching breakeven in FY2022. Actual FY2021 revenue was roughly A$3.7m, about 70% below forecast. This was the core reason for the de-rating.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRoleNotes

Total Brain Limited (Australia)

ASX-listed parent; Sydney corporate office

Deregistered 12 May 2025

Brain Resource, Inc. (USA), trading as Total Brain

US operating subsidiary, San Francisco

Business assets sold to SonderMind (Preqin profile names this entity)

Other subsidiaries

Not publicly disclosed in sources retrieved

—

Segment Margins & Growth (%)

IndicatorFY2018FY2019FY2020

Core corporate / employer revenue growth (%)

2833—

Non-core / other revenue growth (%)

-33-36—

Total revenue growth (%)

8.5-0.548.4

Revenue by Segment

MetricDec 2019Mar 2020Dec 2020

Minimum new ARR signed in quarter (AUD Mn)

—1.9—

Total ARR (AUD Mn)

2.74—4.0

Contracted ARR pipeline (AUD Mn)

——8.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2018FY2019FY2020FY2021FY2022

Revenue (AUD Mn)

2.622.603.863.698.42

Revenue growth (%)

8.5-0.548.4-4.4128.2

Net income attributable (AUD Mn)

-23.10-8.57——-14.50

Net margin (%)

-883-329——-172

Dividends per share (AUD cents)

—0———

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

Metric (AUD Mn)TTM Dec 2022

Revenue

6.34

Cost of revenue

10.01

Gross profit

-3.67

Other expenses

11.05

Net earnings

-14.72

Key Financials and Per-Share Data

MetricFY2018FY2019FY2020FY2022

Cash and equivalents (AUD Mn)

——11.1—

Total debt (AUD Mn)

000—

Net debt (AUD Mn)

——-11.10.50

NTA per share (AUD cents, pre-consolidation)

1.340.68——

Key Financials

MetricFY2019FY2020

Cash receipts from customers (AUD Mn)

2.755.00

Net operating outflow (AUD Mn)

7.026.65

Average monthly net outflow (AUD Mn)

0.5850.554

Margin Analysis (%)

RatioFY2019FY2022

Net margin (%)

-329-172

Debt / equity

0 (no debt)

—

Net debt / EBITDA

Not meaningful (negative EBITDA)

Not meaningful

Share Price & Returns

Reference pointPrice (AUD)Source

5 Sep 2019 (pre-consolidation)

0.052

Kalkine (market cap about A$42m)

Pre-pandemic, early 2020 (post-consolidation)

~0.80

Stockhead

Late 2020 trading range

~0.30

Stockhead

29 Jul 2020

0.32

RaaS

29 Oct 2020

0.38

Motley Fool

Jan 2021 high

~0.45

Stockhead

Late 2021 (after Janssen licence)

0.15

Stockhead

16 Jan 2023

0.046

MarketScreener

Capital return, 14 Feb 2023

0.0475 per share

deListed

Share Price

MetricFY2019FY2020

Year-end reference share price (AUD)

0.0520.32

Dividends per share (AUD)

0—

Analyst Conclusions

Management guidance / consensus. None. The company has been deregistered and no securities exist. Any forward view now concerns the Total Brain assets inside SonderMind, which does not publish financials.

Retrospective bull-case arguments (as they were made in 2020–2021):

  1. Irreplaceable science. The standardized database and iSPOT data could not be replicated cheaply. The Janssen (US$2.2m) and Alto licences proved third parties would pay for them.

  2. Operating leverage. FY2020 showed revenue +48.4% on costs up about 3%, so incremental ARR should have dropped through toward breakeven.

  3. Government scale optionality. IBM/VA expansion from 25,000 to about 200,000 users could have added about A$3.5m of ARR, nearly doubling the business.

Bear-case arguments (which proved correct):

  1. Scale gap. ARR of about A$4m could not fund a competitive US go-to-market against peers backed by hundreds of millions of US dollars.

  2. Conversion failure. Pipelines slipped (COVID delays of up to 9 months; IBM/VA delays). FY2021 revenue of about A$3.7m came in roughly 70% below sell-side forecasts.

  3. Financing dependency. A quarterly burn of about A$2.9m against receipts of about A$0.55m (September 2021 quarter) made dilution or a sale unavoidable once equity markets tightened in 2022.

Catalysts / monitorables (next 12 months). For former shareholders: none, beyond confirming whether the liquidator made any further distribution after the A$0.0475 capital return (the 7 June 2024 loss declaration suggests no material further return). For the successor: whether SonderMind's measurement-based-care and AI tools visibly carry Total Brain's capacity assessments, whether SonderMind raises new capital or pursues an IPO, and whether the iSPOT datasets are licensed further.

Concluding analyst verdict.

Total Brain Limited is a closed file. Its story is common in Australian-listed life-science technology: world-class science, a sub-scale commercial engine, and a capital structure that could not bridge the gap. Over more than two decades, Brain Resource and then Total Brain built something genuinely distinctive: a standardized brain database and the iSPOT treatment-prediction studies. These were credible enough to attract IBM, the US Department of Veterans Affairs, AARP, Janssen and Alto Neuroscience. The 2018 relaunch as a mental-health SaaS platform was strategically sound, and FY2020 briefly showed the operating leverage the model promised: revenue up 48% on flat costs, positive quarterly operating cash flow, and A$11m of net cash.

The execution window closed quickly. COVID-19 hit exactly the long-cycle enterprise and government pipelines Total Brain depended on. Flagship deals slipped, and FY2021 revenue of roughly A$3.7m fell far short of forecasts above A$12m. The US employer mental-health market consolidated around full-stack providers that combined digital tools with therapy, a layer Total Brain never had. With quarterly burn near A$3m, a CEO and CFO departure in late 2021, and the auditor's going-concern emphasis in 2022, the board's US$10m sale to SonderMind was the rational outcome. The forfeited US$3m contingent payment underlined how little negotiating leverage remained. At about 1.7x trailing revenue, the exit valued the science well below its cumulative investment of about A$50m.

For investors, the lesson is that proprietary data creates option value but not a business model unless distribution is in place. Total Brain's real legacy now lives inside SonderMind's measurement-based-care platform, where the original thesis can still be tested: that objective brain-health measurement improves mental-health outcomes. It is no longer testable in public markets. Rating: Not applicable (entity deregistered). Historical assessment: scientifically strong, commercially sub-scale, ultimately a distressed strategic exit.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleAppointedBackground (as disclosed)

Dr Evian Gordon (BSc Hons, MD, MBBCh, PhD)

Founder, Executive Chairman; Chief Medical Officer (by Jan 2022)

8 Aug 2000

Neuroscientist; founded Brain Resource; associated with more than 40 years of brain research per the SonderMind release (Nov 2022); moved across with the business to SonderMind

Matthew (Matt) Mund

Interim CEO (from Nov 2021); previously COO

3 Aug 2017

Operations executive; COO from Nov 2020 per company records

Simon Poidevin

President, Australia & New Zealand

20 Mar 2020

ANZ commercial lead

Matthew Morgan

Non-Executive Director

1 Mar 2016

Authorized ASX releases in 2021; on-market buyer of TTB shares 2018–2019

David Torrible

Non-Executive Director

1 Jun 2019

Not detailed in sources

Nestor Hinzack

Non-Executive Director (per deListed record)

Recorded 16 May 2001

Long-tenured early director

Nathan Jong; Phillip Hains

Company Secretaries

—

Company-secretarial services

“—” = not publicly disclosed.

Board of Directors

NameRoleTenure

Louis Gagnon

Managing Director and CEO

23 May 2017 – 12 Nov 2021

Emil Vasilev

CFO / VP Finance

~2020 – 3 Dec 2021

David Daglio

Non-Executive Director

13 Jan 2020 – 5 Dec 2022

Ajay Arora

Non-Executive Director

8 May 2018 – 13 Jan 2020

Stephen Koslow

Non-Executive Director

1 Mar 2016 – 1 Jun 2019

Gregory Bayer

CEO

15 Mar 2012 – 23 May 2017

Dan Segal

Co-founder; COO/CFO; Executive Director

8 Aug 2000 – 13 Oct 2016

Arthur Toga

Non-Executive Director

16 May 2001 – 1 Mar 2016

Russell Jamison

Non-Executive Director

5 Aug 2003 – 23 Jun 2014

Paul Keating

Non-Executive Director

28 Aug 2001 – 6 Apr 2011

Major Shareholders

HolderStakeDateSource

Mitsubishi UFJ Financial Group, Inc.

5.17% (initial substantial holding)

2019

Kalkine

Zoltan Varga

Convertible noteholder (A$1.28m) and shareholder; equity % not disclosed

Apr 2022

RaaS, Aug 2022

Institutional placees (10 investors, Nov 2019 placement)

Not individually disclosed

Nov 2019

ASX via deListed

Competitive Landscape

Key Competitors

CompetitorSegment overlapOwnershipRelative positioning vs TTB

Lyra Health

Employer mental-health benefits

Private (VC)

Far larger; full-stack therapy plus digital; dominant with Fortune 500

Spring Health

Employer mental health; precision matching

Private (VC)

Precision-psychiatry positioning that directly overlapped TTB's science narrative; much larger funding

Modern Health

Employer mental wellbeing

Private (VC)

Global employer platform; tiered care

Headspace (merged with Ginger, 2021)

Consumer and employer mindfulness; coaching

Private

Brand scale; employer distribution

Calm

Consumer and employer wellbeing

Private

Consumer brand dominance

Talkspace

Virtual therapy; employer and payer

Public (NASDAQ: TALK)

Therapy delivery rather than measurement

Teladoc Health (BetterHelp, Livongo)

Virtual mental health at scale

Public (NYSE: TDOC)

Scale incumbent

Lumos Labs (Lumosity)

Consumer brain training

Private

Overlapped TTB's legacy MyBrainSolutions brain-training proposition

Happify / Twill

Digital mental-health and wellbeing programs

Private

Payer and employer programs

Mindstrong

Digital biomarkers for mental health

Private (wound down; tech acquired by SonderMind)

Closest "measurement-based" analogue; a parallel failure

Alto Neuroscience

Precision psychiatry (biomarker-guided drugs)

Public (NYSE: ANRO, IPO 2024)

Customer for TTB data rather than a competitor

SonderMind

Therapy matching and delivery

Private

Became acquirer

Competitor Detail

MetricTotal Brain (FY2022)

Revenue

A$8.42m

Revenue growth

+128% (one-off licence driven)

Net margin

-172%

Recent Developments

Total Brain Limited produced almost no newsflow in this window because it was deregistered in May 2025. To give a useful register, Part A covers the entity and its successor in the true 18-month window. Part B covers the final 18 months of the listed company's material newsflow (August 2021 – March 2023).

Part A — Entity and successor (Apr 2025 – Oct 2026)

DateEventSignificance
12 May 2025Total Brain Limited deregistered by ASICEntity ceases to exist; a CGT event for any remaining holders (deListed)
2,025SonderMind expands in-network psychiatry to all 50 US states and DC (announced Nov 2025)Shows the scale of the platform that now holds Total Brain's assets (Unify / AI Engineer org profile)
Aug 2025SonderMind provider network reaches about 13,000 cliniciansDistribution base for any Total Brain-derived measurement tools (AI Engineer org profile)
4 Mar 2026SonderMind's President Jennifer Meyer is quoted in Octave's WiseMatch in-network-matching launch releaseShows SonderMind's focus on access and matching infrastructure (CB Insights / Business Wire)
2,026SonderMind app promotes "Sonder", a 24/7 AI companion between sessions, and a SonderMind AI Suite governed by an AI ConstitutionMeasurement and self-care between sessions, the original Total Brain value proposition, now delivered through AI tooling (Similarweb listing; Business Wire)
2,026SonderMind headcount reported at about 577 (Unify, Apr 2026) versus about 1.1k (GetLatka)Sources conflict; both noted

Part B — Final listed-company register (Aug 2021 – Mar 2023)

#DateEventSignificance
1Oct 2021September 2021 quarter 4C: receipts A$0.554m; operating outflow A$2.865mUnsustainable burn
212 Nov 2021CEO/MD Louis Gagnon departs; Matt Mund becomes Interim CEOLeadership transition
33 Dec 2021CFO Emil Vasilev departsFinance leadership gap
4Late 2021US$2.2m Janssen iSPOT-D licence; shares rise more than 50% to 15cNon-dilutive cash
55 Jan 2022Alto Neuroscience iSPOT-D licenceSecond data monetization
611 Mar 2022"Collaborative Care" thought-leadership publicationRepositions toward clinical integration
74–5 Apr 2022Expects A$1.278m funding (convertible note, Zoltan Varga)Bridge financing
83 Aug 2022Trading halt pending significant transactionSale imminent
94–5 Aug 2022Binding US$10m asset sale to SonderMindExit announced
105 Aug 2022Plan disclosed to repay liabilities, return capital, delist and wind upEnd-state defined
1122 Aug 2022Deadline passes for the clinical-services condition tied to the US$3m contingent paymentUS$3m not payable
1230 Aug 2022FY2022 results: revenue A$8.42m, net loss A$14.5mFinal full-year results
13Sep 2022Auditor raises going-concern doubtConfirms funding pressure
1428–29 Sep 2022FY2022 Annual Report and AGM / transaction notice of meetingShareholder process
1530–31 Oct 2022Shareholder call; asset sale completed; shares up about 5%Deal closed
1615 Nov 2022SonderMind announces the acquisition at HLTH 2022Public integration narrative
175 Dec 2022Director David Daglio resignsBoard downsizing
1811 Jan 2023Capital-return payment mechanics (EFT) advisedDistribution process
1931 Jan 2023Shareholder callPre-EGM communication
201 Feb 2023EGM approves delistingFinal approval
2114 Feb 2023A$0.0475 per share capital return paid; delisting date (1 Mar) announcedCash to holders
2228 Feb 2023H1 FY2023 results; securities suspended at closeFinal report
231 Mar 2023Removed from ASX Official ListListing ends
249 Mar 2023Final shareholder callPost-delisting communication
257 Jun 2024Liquidator loss declarationTax event for holders
262 Jul 2024Liquidator activity reportWinding-up progress

Company Snapshot

$5.8M

Revenue

2000

Founded

California, US

Headquarters

SWOT Analysis

Strengths

  • Unique dataset. Described as the world's largest standardized brain database, with more than one million users and about A$50m of cumulative R&D (RaaS 2021; Stockhead).
  • Monetizable research assets. iSPOT-D licensed twice in roughly two months: US$2.2m from Janssen (late 2021) and a licence to Alto Neuroscience (Jan 2022).
  • Blue-chip validation. IBM chose TTB for Mental Fitness 360 (Aug 2019), and the VA was the first government client (2021).
  • Recurring-revenue momentum in 2020. ARR about A$4.0m at December 2020, +46% YoY.
  • Cost discipline in FY2020. Revenue +48.4% with expenses up only about 3% (FY2020 Annual Report via Motley Fool).
  • Debt-free balance sheet after recapitalization. A$11.1m of net cash at 30 June 2020 (RaaS).

Weaknesses

  • Chronic losses. Net loss of A$23.1m (FY2018), A$8.6m (FY2019) and A$14.5m (FY2022).
  • Small revenue base. A$2.6m in FY2019 and A$3.7m in FY2021 (Preqin, currency unconfirmed).
  • Cash burn. Operating outflow of A$2.865m against receipts of A$0.554m in the September 2021 quarter.
  • Customer concentration. A single affinity contract accounted for A$1.3m of ARR, about a third of total ARR in 2020 (Mar 2020 quarterly; Jan 2021 update).
  • Leadership instability at the critical moment. CEO and CFO both departed in Nov–Dec 2021.
  • Forecast credibility gap. RaaS forecast A$12.6m for FY2021 versus about A$3.7m actual. The CY2019 target of US$3.2m revenue was missed.

Opportunities

  • IBM/VA scale-up from 25,000 to about 200,000 users, worth about A$3.5m ARR (company estimate).
  • D2C licence with Hamptons Life (A$6m upfront if completed).
  • Further pharma data licences, following the Janssen and Alto precedents.
  • Insurance-code reimbursement for clinical monitoring (flagged March 2020).
  • HRV biometrics upsell (pilot: 25% stress reduction).
  • Strategic sale to a care-delivery platform. This was realized through SonderMind at US$10m.

Threats

  • Well-funded US competitors: SonderMind alone had raised US$183m (MobiHealthNews, 2022), and Lyra and Spring Health raised far more.
  • Lengthy government procurement: the IBM/VA contract was repeatedly delayed through early 2021.
  • Capital-market closure in 2022: the auditor raised going-concern doubt (Sept 2022).
  • COVID-19 disruption: pipelines delayed up to nine months.
  • Commoditization of mental-health self-assessment tools by large platforms.
  • Contingent consideration risk: the US$3m SonderMind earn-out was forfeited when a customer implementation condition was missed by 22 Aug 2022.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
12 May 2025Total Brain Limited deregistered by ASICEntity ceases to exist; a CGT event for any remaining holders (deListed)
2025SonderMind expands in-network psychiatry to all 50 US states and DC (announced Nov 2025)Shows the scale of the platform that now holds Total Brain's assets (Unify / AI Engineer org profile)
Aug 2025SonderMind provider network reaches about 13,000 cliniciansDistribution base for any Total Brain-derived measurement tools (AI Engineer org profile)
4 Mar 2026SonderMind's President Jennifer Meyer is quoted in Octave's WiseMatch in-network-matching launch releaseShows SonderMind's focus on access and matching infrastructure (CB Insights / Business Wire)
2026SonderMind app promotes "Sonder", a 24/7 AI companion between sessions, and a SonderMind AI Suite governed by an AI ConstitutionMeasurement and self-care between sessions, the original Total Brain value proposition, now delivered through AI tooling (Similarweb listing; Business Wire)
2026SonderMind headcount reported at about 577 (Unify, Apr 2026) versus about 1.1k (GetLatka)Sources conflict; both noted
Oct 2021September 2021 quarter 4C: receipts A$0.554m; operating outflow A$2.865mUnsustainable burn
12 Nov 2021CEO/MD Louis Gagnon departs; Matt Mund becomes Interim CEOLeadership transition
3 Dec 2021CFO Emil Vasilev departsFinance leadership gap
Late 2021US$2.2m Janssen iSPOT-D licence; shares rise more than 50% to 15cNon-dilutive cash
5 Jan 2022Alto Neuroscience iSPOT-D licenceSecond data monetization
11 Mar 2022"Collaborative Care" thought-leadership publicationRepositions toward clinical integration
4–5 Apr 2022Expects A$1.278m funding (convertible note, Zoltan Varga)Bridge financing
3 Aug 2022Trading halt pending significant transactionSale imminent
4–5 Aug 2022Binding US$10m asset sale to SonderMindExit announced
5 Aug 2022Plan disclosed to repay liabilities, return capital, delist and wind upEnd-state defined
22 Aug 2022Deadline passes for the clinical-services condition tied to the US$3m contingent paymentUS$3m not payable
30 Aug 2022FY2022 results: revenue A$8.42m, net loss A$14.5mFinal full-year results
Sep 2022Auditor raises going-concern doubtConfirms funding pressure
28–29 Sep 2022FY2022 Annual Report and AGM / transaction notice of meetingShareholder process
30–31 Oct 2022Shareholder call; asset sale completed; shares up about 5%Deal closed
15 Nov 2022SonderMind announces the acquisition at HLTH 2022Public integration narrative
5 Dec 2022Director David Daglio resignsBoard downsizing
11 Jan 2023Capital-return payment mechanics (EFT) advisedDistribution process
31 Jan 2023Shareholder callPre-EGM communication
1 Feb 2023EGM approves delistingFinal approval
14 Feb 2023A$0.0475 per share capital return paid; delisting date (1 Mar) announcedCash to holders
28 Feb 2023H1 FY2023 results; securities suspended at closeFinal report
1 Mar 2023Removed from ASX Official ListListing ends
9 Mar 2023Final shareholder callPost-delisting communication
7 Jun 2024Liquidator loss declarationTax event for holders
2 Jul 2024Liquidator activity reportWinding-up progress

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment: Total ARR rose from AUD 2.7 Mn in Dec 2019 to AUD 4 Mn in Dec 2020.
Total Brain Limited — Revenue by Segment
Series (AUD Mn)Dec 2019Mar 2020Dec 2020
Total ARR2.7—4
Minimum new ARR signed in quarter—1.9—
Contracted ARR pipeline——8.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. deListed Australia, Total Brain Limited company record (listing, delisting, deregistration, name history, director register, event log) (delisted.com.au)
  2. Total Brain FY2019 Appendix 4E / Annual Report (ASX, 30 Aug 2019) (announcements.asx.com.au)
  3. Brain Resource FY2018 Annual Report (totalbrain.com)
  4. September 2018 Quarterly Report (totalbrain.com)
  5. December 2018 Quarterly Report (totalbrain.com)
  6. September 2019 Quarterly 4C (totalbrain.com)
  7. March 2020 Quarterly 4C (totalbrain.com)
  8. March 2021 Quarterly 4C (info.totalbrain.com)
  9. RaaS Update Report, 30 Jul 2020 (strawman.com)
  10. RaaS Update Report, 2 Jul 2020 (totalbrain.com)
  11. RaaS Flash Comment (Hamptons Life), 4 May 2021 (info.totalbrain.com)
  12. RaaS, "Binding agreement to sell assets to SonderMind", 8 Aug 2022 (research-tree.com)
  13. Listcorp, "Sale of main undertaking" (ASX, 5 Aug 2022) (listcorp.com)
  14. The Market Herald via Sydney Aus Today (SonderMind sale terms) (sydneyaustoday.com)
  15. MarketScreener, SonderMind agreement and contingent payment / delisting summary (marketscreener.com)
  16. MarketScreener, completion of asset sale (marketscreener.com)
  17. MarketScreener, OTC (BRRZY) news log (marketscreener.com)
  18. MarketScreener, FY2022 financial summary and funding note (marketscreener.com)
  19. Business Wire, SonderMind acquisition release (15 Nov 2022) (businesswire.com)
  20. MobiHealthNews, SonderMind acquires Total Brain (mobihealthnews.com)
  21. Fierce Healthcare, HLTH22 SonderMind / Total Brain (fiercehealthcare.com)
  22. Behavioral Health Business (Nov 2022) (bhbusiness.com)
  23. PrivSource, SonderMind deal register (privsource.com)
  24. Preqin profile (deal value, FY2021 revenue) (preqin.com)
  25. Stockhead, Janssen licence (stockhead.com.au)
  26. Stockhead, IBM / VA rollout (stockhead.com.au)
  27. Stockhead, ARR and growth pathway (Jan 2021) (stockhead.com.au)
  28. Total Brain release, Alto Neuroscience licence (5 Jan 2022) (totalbrain.com)
  29. Total Brain release, CEO award (23 Dec 2020) (totalbrain.com)
  30. Motley Fool Australia (FY2020 revenue growth), 29 Oct 2020 (fool.com.au)
  31. Kalkine, Sept 2019 (kalkine.com.au)
  32. Yahoo Finance / Simply Wall St (2019) (finance.yahoo.com)
  33. Simply Wall St, TTBL.F TTM data (simplywall.st)
  34. Eulerpool, TTB.AX (eulerpool.com)
  35. FNArena, "Brain Explosion" (May 2012) (fnarena.com)
  36. FNArena (May 2011) (fnarena.com)
  37. Business News, Total Brain profile (businessnews.com.au)
  38. Crunchbase, Dan Segal bio (crunchbase.com)
  39. MarketBeat, ASX:TTB (marketbeat.com)
  40. CB Insights, SonderMind (cbinsights.com)
  41. Unify, SonderMind headcount (Apr 2026) (unifygtm.com)
  42. AI Engineer, SonderMind org profile (2026) (ai.engineer)
  43. GetLatka, SonderMind (getlatka.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.